Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.75 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157820 | 0.89 | CA5A (0.71) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL15838648 | 0.88 | CA5A (0.69) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL8157880 | 0.87 | CA5A (0.68) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| Rufinamide SCHEMBL230448 | 0.86 | CA5A (1.00) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| Rufinamide SCHEMBL20769779 | 0.86 | CA5A (1.00) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL9857936 | 0.85 | CA5A (0.66) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| Rufinamide SCHEMBL17372728 | 0.84 | CA5A (0.97) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL460913 | 0.84 | CA5A (0.76) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL6738882 | 0.83 | CA5A (0.74) | CA5AKLKB1CYP2C19ALDH1A1LMNA | |
| SCHEMBL460954 | 0.83 | CA5A (0.74) | CA5AKLKB1CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021449-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200399229-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-107406420-B | Substituted triazoles and methods related thereto | 纽罗克里生物科学有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10738017-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190169137-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10138214-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9718789-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160221968-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-08-04 | — | — | US | disclosed |
| WO-2014097137-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEIZURES AND NEUROLOGIC DISEASES | KANDULA MAHESH (IN) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021449-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
| US-20160221968-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
| US-20200399229-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
| US-10138214-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
| US-10738017-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
| US-20190169137-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | CA5A 575/4885KLKB1 3091/4885CYP2C19 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.